Claire Briet1,2, Mirela Diana Ilie1, Emmanuelle Kuhn1,3,4,5, Luigi Maione1,3,4,5, Sylvie Brailly-Tabard3,4,5, Sylvie Salenave1, Bertrand Cariou6, Philippe Chanson7,8,9,10. 1. Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, F-94275, Le Kremlin Bicêtre, France. 2. Institut MITOVASC, INSERM U1083, Université d'Angers, Département d'Endocrinologie, Diabétologie et Nutrition, Centre Hospitalier Universitaire d'Angers, F-49933, Angers, France. 3. Univ Paris-Sud, Faculté de Médecine Paris-Sud, F-94276, Le Kremlin Bicêtre, France. 4. Unité Mixte de Recherche-S1185, F-94276, Le Kremlin Bicêtre, France. 5. Institut National de la Santé et de la Recherche Médicale (INSERM) U1185, F-94276, Le Kremlin Bicêtre, France. 6. l'Institut du Thorax, INSERM, CNRS, Univ Nantes, CHU Nantes, F-44000, Nantes, France. 7. Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, F-94275, Le Kremlin Bicêtre, France. philippe.chanson@bct.aphp.fr. 8. Univ Paris-Sud, Faculté de Médecine Paris-Sud, F-94276, Le Kremlin Bicêtre, France. philippe.chanson@bct.aphp.fr. 9. Unité Mixte de Recherche-S1185, F-94276, Le Kremlin Bicêtre, France. philippe.chanson@bct.aphp.fr. 10. Institut National de la Santé et de la Recherche Médicale (INSERM) U1185, F-94276, Le Kremlin Bicêtre, France. philippe.chanson@bct.aphp.fr.
Abstract
CONTEXT: Untreated acromegaly is associated with increased morbidity and mortality due to malignant, cardiovascular, and cerebrovascular disorders. Effective treatment of acromegaly reduces excess mortality, but its impact on cardiovascular risk factors and metabolic parameters are poorly documented. AIM: We analyzed changes in cardiovascular risk factors and metabolic parameters in patients receiving various treatment modalities. PATIENTS AND METHODS: We retrospectively studied 96 patients with acromegaly, both at diagnosis and after IGF-I normalization following surgery alone (n = 51) or medical therapy with first generation somatostatin analogues (SSA, n = 23), or pegvisomant (n = 22). Duration of follow-up was 77 (42-161) months, 75 (42-112) months, and 62 (31-93) months, in patients treated with surgery alone, SSA, and pegvisomant, respectively. In all the cases except four, patients treated medically had underwent previous unsuccessful surgery. RESULTS: IGF-I normalization was associated with increased body weight, decreased systolic blood pressure (SBP) in hypertensive patients, decreased fasting plasma glucose (FPG) and HOMA-IR and HOMA-B levels, increased HDL cholesterol (HDLc); whereas, LDL cholesterol (LDLc) was not significantly different. Plasma PCSK9 levels were unchanged in patients with available values. Cardiovascular and metabolic changes varied with the treatment modality: surgery, but not pegvisomant, had a beneficial effect on SBP; FPG decreased after surgery but increased after SSA; the decline in HOMA-IR was only significant after surgery; pegvisomant significantly increased LDLc and total cholesterol; whereas SA increased HDLc and had no effect on LDLc levels. CONCLUSION: Treatments used to normalize IGF-I levels in patients with acromegaly could have differential effects on cardiovascular risk factors and metabolic parameters.
CONTEXT: Untreated acromegaly is associated with increased morbidity and mortality due to malignant, cardiovascular, and cerebrovascular disorders. Effective treatment of acromegaly reduces excess mortality, but its impact on cardiovascular risk factors and metabolic parameters are poorly documented. AIM: We analyzed changes in cardiovascular risk factors and metabolic parameters in patients receiving various treatment modalities. PATIENTS AND METHODS: We retrospectively studied 96 patients with acromegaly, both at diagnosis and after IGF-I normalization following surgery alone (n = 51) or medical therapy with first generation somatostatin analogues (SSA, n = 23), or pegvisomant (n = 22). Duration of follow-up was 77 (42-161) months, 75 (42-112) months, and 62 (31-93) months, in patients treated with surgery alone, SSA, and pegvisomant, respectively. In all the cases except four, patients treated medically had underwent previous unsuccessful surgery. RESULTS:IGF-I normalization was associated with increased body weight, decreased systolic blood pressure (SBP) in hypertensivepatients, decreased fasting plasma glucose (FPG) and HOMA-IR and HOMA-B levels, increased HDL cholesterol (HDLc); whereas, LDL cholesterol (LDLc) was not significantly different. Plasma PCSK9 levels were unchanged in patients with available values. Cardiovascular and metabolic changes varied with the treatment modality: surgery, but not pegvisomant, had a beneficial effect on SBP; FPG decreased after surgery but increased after SSA; the decline in HOMA-IR was only significant after surgery; pegvisomant significantly increased LDLc and total cholesterol; whereas SA increased HDLc and had no effect on LDLc levels. CONCLUSION: Treatments used to normalize IGF-I levels in patients with acromegaly could have differential effects on cardiovascular risk factors and metabolic parameters.
Authors: Peter Wiesli; René Bernays; Michael Brändle; Cornelia Zwimpfer; Heidi Seiler; Jürgen Zapf; Giatgen A Spinas; Christoph Schmid Journal: Clin Chim Acta Date: 2005-02 Impact factor: 3.786
Authors: Caio B Vianna; Marcelo L C Vieira; Charles Mady; Bernardo Liberman; Anai E S Durazzo; Mirta Knoepfelmacher; Luiz R Salgado; Jose A F Ramires Journal: Am Heart J Date: 2002-05 Impact factor: 4.749
Authors: C Dimopoulou; C Sievers; H U Wittchen; L Pieper; J Klotsche; J Roemmler; J Schopohl; H J Schneider; G K Stalla Journal: Pituitary Date: 2010-09 Impact factor: 4.107
Authors: Susan G Lakoski; Thomas A Lagace; Jonathan C Cohen; Jay D Horton; Helen H Hobbs Journal: J Clin Endocrinol Metab Date: 2009-04-07 Impact factor: 5.958
Authors: Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli Journal: Endocrine Date: 2020-02-14 Impact factor: 3.633
Authors: Betina Biagetti; J R Herance; Roser Ferrer; Anna Aulinas; Martina Palomino-Schätzlein; Jordi Mesa; J P Castaño; Raul M Luque; Rafael Simó Journal: J Clin Med Date: 2019-09-26 Impact factor: 4.241